Research page

CJC/Ipa Blend

CJC/Ipa Blend 5 mg/5 mg. For research use only
Calculate dose

Specification

NameCJC/Ipa Blend
Catalog sizes5 mg/5 mg
Adopted bacteriostatic water10 mg + 2.0 mL = 5 mg/mL

Overview

CJC/Ipa Blend places, on the TRACE label, 5 mg of CJC-1295 and 5 mg of ipamorelin (10 mg total). They are two different secretagogues of the growth-hormone axis: one related to GHRH and one to secretagogue (ghrelin) receptors. They stimulate a signal; they do not replace growth hormone.

Mechanism under study

CJC-1295 has been studied as a GHRH analog. The DAC (drug-affinity complex) form lengthens its presence in blood in the published work. Ipamorelin has been described as a pentapeptide selective for the secretagogue receptor, with less accompanying cortisol and prolactin release than older secretagogues in the laboratory reports cited.

What published research has reported

A 2006 study in The Journal of Clinical Endocrinology & Metabolism evaluated CJC-1295, the long-acting analog, in healthy adults and described a sustained rise in growth hormone and IGF-1 during the observation period. It is not a study of this blend.

Ipamorelin was presented in the European Journal of Endocrinology in 1998 as a selective secretagogue in laboratory models. TRACE does not turn that paper into a schedule.

Composition and mass

Label: 5 mg / 5 mg, 10 mg total. The adopted sheet uses 2 mL of bacteriostatic water (5 mg/mL of the total). If the label split is exact, each peptide sits at 2.5 mg/mL. That arithmetic is not a recommended amount.

Reconstitution

mgmLmg/mL
102.05In the catalog

Calculate dose

Storage and handling

Lyophilized material cool, dry, and protected from light. Dissolved: refrigerate at 2–8 °C, do not freeze, 28-day horizon.

Regulatory status

Research material. It is not growth hormone, not a medicine approved for a general use, and not a supplement. The statements on this page have not been evaluated by the FDA.

References